|
"hsiao cf"的相關文件
顯示項目 46-70 / 204 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2018-07-17 |
Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG)
|
Hong, RL;Hsiao, CF;Ting, LL;Ko, JY;Wang, CW;Chang, JTC;Lou, PJ;Wang, HM;Tsai, MH;Lai, SC;Liu, TW |
| 國家衛生研究院 |
2018-04-07 |
The clinical impact of the novel tumor marker DR-70 in unresectable gastric cancer patients
|
Hung, YP;Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2018-01-01 |
Use of interval estimations in design and evaluation of multiregional clinical trials with continuous outcomes
|
Chiang, C;Hsiao, CF |
| 國家衛生研究院 |
2017-11-23 |
Prediction of plasma efavirenz concentrations among HIV-positive patients taking efavirenz-containing combination antiretroviral therapy
|
Huang, SH;Lin, SW;Chang, SY;Lin, YT;Chiang, C;Hsiao, CF;Sun, HY;Liu, WC;Su, YC;Hung, CC;Chang, SC |
| 國家衛生研究院 |
2017-11 |
Intake of potassium- and magnesium-enriched salt improves functional outcome after stroke: A randomized, multicenter, double-blind controlled trial
|
Pan, WH;Lai, YH;Yeh, WT;Chen, JR;Jeng, JS;Bai, CH;Lin, RT;Lee, TH;Chang, KC;Lin, HJ;Hsiao, CF;Chern, CM;Lien, LM;Liu, CH;Chen, WH;Chang, A |
| 國家衛生研究院 |
2017-10 |
Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma
|
Chie, WC;Blazeby, JM;Hsiao, CF;Chiu, HC;Poon, RT;Mikoshiba, N;Al-Kadhim, G;Heaton, N;Calara, J;Collins, P;Caddick, K;Costantini, A;Vilgrain, V;Chiang, C;Group, EOTRC Quality of Life |
| 國家衛生研究院 |
2017-09 |
A tolerance interval approach to assessing the biosimilarity of follow-on biologics
|
Chen, CT;Tsou, HH;Hsiao, CF;Lai, YH;Chang, WJ;Liu, JT |
| 國家衛生研究院 |
2017-08-30 |
Use of a Bayesian approach in the design and evaluation of NCE2s
|
Wang, CY;Chang, LC;Lin, MS;Hsiao, CF;Huang, JD |
| 國家衛生研究院 |
2017-06-30 |
Sample size determination for a specific region in multiregional clinical trials with multiple co-primary endpoints
|
Huang, WS;Hung, HN;Hamasaki, T;Hsiao, CF |
| 國家衛生研究院 |
2017-05 |
Efficient group-sequential designs for monitoring two time-to-event outcomes in clinical trials
|
Hamasaki, T;Asakura, K;Sugimoto, T;Evans, SR;Yamamoto, H;Hsiao, CF |
| 國家衛生研究院 |
2017-03 |
Genetic modifiers of progression-free survival in never-smoking lung adenocarcinoma patients treated with first-line TKIs
|
Chang, IS;Jiang, SS;Yang, JC;Su, WC;Chien, LH;Hsiao, CF;Lee, JH;Chen, CY;Chen, CH;Chang, GC;Wang, Z;Lo, FY;Chen, KY;Wang, WC;Chen, YM;Huang, MS;Tsai, YH;Su, YC;Hsieh, WS;Shih, WC;Shieh, SH;Yang, TY;Lan, Q;Rothman, N;Chen, CJ;Chanock, SJ;Yang, PC;Hsiung, CA |
| 國家衛生研究院 |
2017-03 |
An approach for sample size determination of average bioequivalence based on interval estimation
|
Chiang, C;Hsiao, CF |
| 國家衛生研究院 |
2017-02 |
Integrated care for geriatric frailty and sarcopenia: A randomized control trial
|
Chan, DCD;Tsou, HH;Chang, CB;Yang, RS;Tsauo, JY;Chen, CY;Hsiao, CF;Hsu, YT;Chen, CH;Chang, SF;Hsiung, CA;Kuo, KN |
| 國家衛生研究院 |
2016-11-11 |
Assessing benefit and consistency of treatment effect under a discrete random effects model in multiregional clinical trials
|
Liu, JT;Chen, CT;Lan, KKG;Tzeng, CS;Hsiao, CF;Tsou, HH |
| 國家衛生研究院 |
2016-10 |
The role of pre-treatment plasma Epstein-Barr virus (EBV) DNA as a predictive biomarker of induction chemotherapy for stage IVA or IVB nasopharyngeal carcinoma (NPC) patients - A Subgroup Analysis on Taiwan Cooperative Oncology Group (TCOG) 1303 study
|
Kao, HF;Hsiao, CF;Lai, SC;Wang, CW;Ko, JY;Lo, PJ;Lee, TJ;Liu, TW;Hong, RL |
| 國家衛生研究院 |
2016-06 |
Assessing the consistency of the treatment effect under the discrete random effects model in multiregional clinical trials
|
Liu, JT;Tsou, HH;Gordon Lan, KK;Chen, CT;Lai, YH;Chang, WJ;Tzeng, CS;Hsiao, CF |
| 國家衛生研究院 |
2016-04-21 |
The discrete random-effects model-assessing benefit and consistency of treatment effect
|
Tsou, HH;Lan, KKG;Liu, JT;Hsiao, CF |
| 國家衛生研究院 |
2016-01 |
A phase II study of sequential capecitabine plus oxaliplatin followed by docetaxel plus capecitabine in patients with unresectable gastric adenocarcinoma: The TCOG 3211 clinical trial
|
Chen, MH;Lin, J;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
| 國家衛生研究院 |
2015-10 |
Quality of life changes in patients undergoing treatment for hepatocellular carcinoma
|
Chie, WC;Yu, F;Li, M;Baccaglini, L;Blazeby, JM;Hsiao, CF;Chiu, HC;Poon, RT;Mikoshiba, N;Al-Kadhimi, G;Heaton, N;Calara, J;Collins, P;Caddick, K;Costantini, A;Vilgrain, V;Chiang, C |
| 國家衛生研究院 |
2015-10 |
Estrogen receptor gene polymorphisms and lung adenocarcinoma risk in never-smoking women
|
Chen, KY;Hsiao, CF;Chang, GC;Tsai, YH;Su, WC;Chen, YM;Huang, MS;Tsai, FY;Jiang, SS;Chang, IS;Chen, CY;Hsiung, CA;Chen, CJ;Yang, PC |
| 國家衛生研究院 |
2015-09-01 |
Chemokine IP-10 is correlated with cardiac responses and status of infection with HIV and HCV in methadone maintenance patients
|
Liu, SW;Liu, YL;Hwang, LL;Wang, SC;Kuo, HW;Wu, SL;Dai, YWE;Liu, SC;Ho, IK;Chen, ACH;Hsiao, CF;Tsou, HH |
| 國家衛生研究院 |
2015-07 |
Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: A report from the female lung cancer consortium in Asia
|
Machiela, MJ;Hsiung, CA;Shu, XO;Seow, WJ;Wang, Z;Matsuo, K;Hong, YC;Seow, A;Wu, C;Hosgood, HD;Chen, K;Wang, JC;Wen, W;Cawthon, R;Chatterjee, N;Hu, W;Caporaso, NE;Park, JY;Chen, CJ;Kim, YH;Kim, YT;Landi, MT;Shen, H;Lawrence, C;Burdett, L;Yeager, M;Chang, IS;Mitsudomi, T;Kim, HN;Chang, GC;Bassig, BA;Tucker, M;Wei, F;Yin, Z;An, SJ;Qian, B;Lee, VHF;Lu, D;Liu, J;Jeon, HS;Hsiao, CF;Sung, JS;Kim, JH;Gao, YT;Tsai, YH;Jung, YJ;Guo, H;Hu, Z;Hutchinson, A;Wang, WC;Klein, RJ;Chung, CC;Oh, IJ;Chen, KY;Berndt, SI;Wu, W;Chang, J;Zhang, XC;Huang, MS;Zheng, H;Wang, J;Zhao, X;Li, Y;Choi, JE;Su, WC;Park, KH;Sung, SW;Chen, YM;Liu, L;Kang, CH;Hu, L;Chen, CH;Pao, W;Kim, YC;Yang, TY;Xu, J;Guan, P;Tan, W;Su, J;Wang, CL;Li, H;Sihoe, ADL;Zhao, Z;Chen, Y;Choi, YY;Hung, JY;Kim, JS;Yoon, HI;Cai, Q;Lin, CC;Park, IK;Xu, P;Dong, J;Kim, C;He, Q;Perng, RP;Kohno, T;Kweon, SS;Chen, CY;Vermeulen, RCH,.;et al. |
| 國家衛生研究院 |
2015-05 |
Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study
|
Chen, LT;Jeng, LB;Hsiao, CF;Wu, CC;Lee, WC;Wang, TE;Lee, PH;Chen, CL;Chen, IS;Lee, KT;Hsieh, CB;Hwang, WS;Yang, MD;Yang, YS;Lin, DY;Chen, MF;Chen, PJ;Taiwan Cooperative Oncology, G |
| 國家衛生研究院 |
2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial
|
Chen, MH;Lin, JS;Hsiao, CF;Shan, YS;Chen, YC;Chen, LT;Liu, TW;Li, CP;Chao, Y |
顯示項目 46-70 / 204 (共9頁)
<< < 1 2 3 4 5 6 7 8 9 > >>
每頁顯示[10|25|50]項目
|
